caa a22 4500 60618001X CHVBK 20210128100804.0 cr unu---uuuuu 210128e20150801xx s 000 0 eng 10.1007/s11136-015-0925-7 doi (NATIONALLICENCE)springer-10.1007/s11136-015-0925-7 Assessment of Parkinson's disease levodopa-induced dyskinesia: a qualitative research study [Elektronische Daten] [William Lenderking, Sally Mannix, Jennifer Petrillo, Christopher Kenney, Amanda Landrian, Anette-Eleonore Schrag] Background and objectives: The 26-item Parkinson disease dyskinesia scale (PDYS-26) was developed to assess the impact of Parkinson's disease levodopa-induced dyskinesias (PD-LID). The purpose of this qualitative research study was to assess the content validity of the PDYS-26 in an independent sample and to use the findings to suggest a conceptual framework around the impact of PD-LID. Methods: PD patients experiencing LID and their caregivers were recruited from four US clinical sites. Stage I involved 22 qualitative concept elicitation interviews with patients and caregivers, and 11 qualitative cognitive interviews (CI) with patients about the PDYS-26. The PDYS-26 was modified based on Stage I findings. Stage II consisted of 13 CI on the Modified PDYS. Results: Forty-six participants were interviewed across both stages of the study. Patient mean age was 67.3 (SD±9.55) years; 19 (54.3%) female; 34 (97.1%) white. The content validity of the PDYS-26 was generally supported. A revised conceptual framework with three hypothesized domains (body control, activities of daily living, social consequences) was developed. Modifications were made to the PDYS-26 (i.e., emphasizing LID in the instructions; response scale modification; deleting or modifying items), which resulted in the 22-item Modified PDYS. Conclusions: Stage I and II findings suggested a number of modifications to the scale in order to improve the content validity. Psychometric testing of the revised scale with a larger patient sample is suggested to evaluate item performance, establish scoring, and provide quantitative support for the conceptual framework. Springer International Publishing Switzerland, 2015 Parkinson's disease nationallicence Levodopa nationallicence Levodopa-induced dyskinesia nationallicence Patient-reported Outcomes nationallicence Qualitative research nationallicence Lenderking William Evidera, 430 Bedford Street, Suite 300, Lexington, MA, USA aut Mannix Sally Evidera, Bethesda, MD, USA aut Petrillo Jennifer Novartis AG, Basel, Switzerland aut Kenney Christopher Formerly Novartis Pharmaceuticals Corp., East Hanover, NJ, USA aut Landrian Amanda Evidera, Bethesda, MD, USA aut Schrag Anette-Eleonore University College London, London, UK aut Quality of Life Research Springer International Publishing 24/8(2015-08-01), 1899-1910 0962-9343 24:8<1899 2015 24 11136 https://doi.org/10.1007/s11136-015-0925-7 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s11136-015-0925-7 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Lenderking William Evidera, 430 Bedford Street, Suite 300, Lexington, MA, USA aut NATIONALLICENCE 700 1- Mannix Sally Evidera, Bethesda, MD, USA aut NATIONALLICENCE 700 1- Petrillo Jennifer Novartis AG, Basel, Switzerland aut NATIONALLICENCE 700 1- Kenney Christopher Formerly Novartis Pharmaceuticals Corp., East Hanover, NJ, USA aut NATIONALLICENCE 700 1- Landrian Amanda Evidera, Bethesda, MD, USA aut NATIONALLICENCE 700 1- Schrag Anette-Eleonore University College London, London, UK aut NATIONALLICENCE 773 0- Quality of Life Research Springer International Publishing 24/8(2015-08-01), 1899-1910 0962-9343 24:8<1899 2015 24 11136